1. Home
  2. PETS vs GNLX Comparison

PETS vs GNLX Comparison

Compare PETS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PETS
  • GNLX
  • Stock Information
  • Founded
  • PETS 1996
  • GNLX 2001
  • Country
  • PETS United States
  • GNLX United States
  • Employees
  • PETS N/A
  • GNLX N/A
  • Industry
  • PETS Retail-Drug Stores and Proprietary Stores
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PETS Consumer Staples
  • GNLX Health Care
  • Exchange
  • PETS Nasdaq
  • GNLX Nasdaq
  • Market Cap
  • PETS 87.1M
  • GNLX 81.0M
  • IPO Year
  • PETS N/A
  • GNLX 2023
  • Fundamental
  • Price
  • PETS $3.79
  • GNLX $2.21
  • Analyst Decision
  • PETS Buy
  • GNLX Strong Buy
  • Analyst Count
  • PETS 2
  • GNLX 3
  • Target Price
  • PETS $5.25
  • GNLX $32.33
  • AVG Volume (30 Days)
  • PETS 489.9K
  • GNLX 342.2K
  • Earning Date
  • PETS 07-29-2024
  • GNLX 08-12-2024
  • Dividend Yield
  • PETS 8.07%
  • GNLX N/A
  • EPS Growth
  • PETS N/A
  • GNLX N/A
  • EPS
  • PETS N/A
  • GNLX N/A
  • Revenue
  • PETS $281,064,000.00
  • GNLX $8,000.00
  • Revenue This Year
  • PETS $2.07
  • GNLX N/A
  • Revenue Next Year
  • PETS $4.31
  • GNLX N/A
  • P/E Ratio
  • PETS N/A
  • GNLX N/A
  • Revenue Growth
  • PETS 9.54
  • GNLX N/A
  • 52 Week Low
  • PETS $3.63
  • GNLX $1.71
  • 52 Week High
  • PETS $15.08
  • GNLX $30.44
  • Technical
  • Relative Strength Index (RSI)
  • PETS 42.93
  • GNLX 44.53
  • Support Level
  • PETS $3.63
  • GNLX $2.28
  • Resistance Level
  • PETS $4.13
  • GNLX $2.70
  • Average True Range (ATR)
  • PETS 0.17
  • GNLX 0.27
  • MACD
  • PETS -0.00
  • GNLX 0.06
  • Stochastic Oscillator
  • PETS 29.63
  • GNLX 50.51

About PETS PetMed Express Inc.

PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies primarily to retail consumers.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: